Split GFP complementation assay: A novel approach to quantitatively measure aggregation of tau in situ: Effects of GSK3β activation and caspase 3 cleavage

Journal of Neurochemistry

Volumn 103, Issue 6, 2007, Pages 2529-2539

  Chun, Wanjoo ^a,d   Waldo, Geoffrey S ^b   Johnson, Gail V W ^a,c,e  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Kangwon National University   (South Korea)

^e UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Caspase 3; GSK3 ; Neurofibrillary tangles; Pseudophosporylation; Split GFP complementation; Tau

Indexed keywords

CASPASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GREEN FLUORESCENT PROTEIN; TAU PROTEIN;

ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS;

BINDING SITES; BIOLOGICAL ASSAY; BRAIN; CASPASE 3; CELL LINE; ENZYME ACTIVATION; FLUORESCENCE; GLYCOGEN SYNTHASE KINASE 3; GREEN FLUORESCENT PROTEINS; HUMANS; MACROMOLECULAR SUBSTANCES; MICROTUBULES; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; PRECIPITIN TESTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SENSITIVITY AND SPECIFICITY; SERINE; TAU PROTEINS; TAUOPATHIES;

EID: 36448995426     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04941.x     Document Type: Article

References (53)

1. Abraha A., Ghoshal N., Gamblin T. C., Cryns V., Berry R. W., Kuret J. Binder L. I. (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J. Cell Sci. 113 (Pt. 21 3737 3745.
2. Alonso A. C., Grundke-Iqbal I. Iqbal K. (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2, 783 787.
3. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I. Iqbal K. (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl Acad. Sci. USA 98, 6923 6928.
4. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K. L., Barde Y. A., Duff K. Davies P. (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582 590.
5. Avila J. (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 580, 2922 2927.
6. Barghorn S., Zheng-Fischhofer Q., Ackmann M., Biernat J., von Bergen M., Mandelkow E. M. Mandelkow E. (2000) Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39, 11714 11721.
7. von Bergen M., Barghorn S., Li L., Marx A., Biernat J., Mandelkow E. M. Mandelkow E. (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J. Biol. Chem. 276, 48165 48174.
8. Bhat R. V. Budd S. L. (2002) GSK3beta signalling: casting a wide net in Alzheimer's disease. Neurosignals 11, 251 261.
9. Binder L. I., Guillozet-Bongaarts A. L., Garcia-Sierra F. Berry R. W. (2005) Tau, tangles, and Alzheimer's disease. Biochim. Biophys. Acta 1739, 216 223.
10. Cabantous S. Waldo G. S. (2006) In vivo and in vitro protein solubility assays using split GFP. Nat. Methods 3, 845 854.
11. Cabantous S., Terwilliger T. C. Waldo G. S. (2005) Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein. Nat. Biotechnol. 23, 102 107.
12. Carmel G., Mager E. M., Binder L. I. Kuret J. (1996) The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J. Biol. Chem. 271, 32789 32795.
13. Caughey B. Lansbury P. T. (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267 298.
14. Cho J. H. Johnson G. V. (2003) Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J. Biol. Chem. 278, 187 193.
15. Cho J. H. Johnson G. V. (2004) Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J. Biol. Chem. 279, 54716 54723.
16. Chun W. Johnson G. V. (2007) The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci. 12, 733 756.
17. Cotman C. W., Poon W. W., Rissman R. A. Blurton-Jones M. (2005) The role of caspase cleavage of tau in Alzheimer disease neuropathology. J. Neuropathol. Exp. Neurol. 64, 104 112.
18. Ding H., Matthews T. A. Johnson G. V. (2006) Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J. Biol. Chem. 281, 19107 19114.
19. Eidenmuller J., Fath T., Hellwig A., Reed J., Sontag E. Brandt R. (2000) Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. Biochemistry 39, 13166 13175.
20. Eldar-Finkelman H. (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8, 126 132.
21. Gamblin T. C., Chen F., Zambrano A. et al. (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl Acad. Sci. USA 100, 10032 10037.
22. Gotz J., Streffer J. R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P. Chen F. (2004) Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 9, 664 683.
23. Grober E., Dickson D., Sliwinski M. J., Buschke H., Katz M., Crystal H. Lipton R. B. (1999) Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 20, 573 579.
24. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y. C., Zaidi M. S. Wisniewski H. M. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084 6089.
25. Haase C., Stieler J. T., Arendt T. Holzer M. (2004) Pseudophosphorylation of tau protein alters its ability for self-aggregation. J. Neurochem. 88, 1509 1520.
26. Johnson G. V., Seubert P., Cox T. M., Motter R., Brown J. P. Galasko D. (1997) The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J. Neurochem. 68, 430 433.
27. Jope R. S. Johnson G. V. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95 102.
28. Kang H. J., Yoon W. J., Moon G. J., Kim D. Y., Sohn S., Kwon H. J. Gwag B. J. (2005) Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease. Neurobiol. Dis. 18, 450 458.
29. Khlistunova I., Biernat J., Wang Y., Pickhardt M., von Bergen M., Gazova Z., Mandelkow E. Mandelkow E. M. (2006) Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205 1214.
30. Kosik K. S., Joachim C. L. Selkoe D. J. (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044 4048.
31. Kuret J., Congdon E. E., Li G., Yin H., Yu X. Zhong Q. (2005) Evaluating triggers and enhancers of tau fibrillization. Microsc. Res. Tech. 67, 141 155.
32. Lee V. M., Goedert M. Trojanowski J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121 1159.
33. Leroy K., Boutajangout A., Authelet M., Woodgett J. R., Anderton B. H. Brion J. P. (2002) The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol (Berl) 103, 91 99.
34. Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R. Avila J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27 39.
35. Meares G. P. Jope R. S. (2007) Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J. Biol. Chem. 282, 16989 17001.
36. Necula M. Kuret J. (2005) Site-specific pseudophosphorylation modulates the rate of tau filament dissociation. FEBS Lett. 579, 1453 1457.
37. Otvos Jr. L., Feiner L., Lang E., Szendrei G. I., Goedert M. Lee V. M. (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669 673.
38. Ozawa T., Sako Y., Sato M., Kitamura T. Umezawa Y. (2003) A genetic approach to identifying mitochondrial proteins. Nat. Biotechnol. 21, 287 293.
39. Phiel C. J., Wilson C. A., Lee V. M. Klein P. S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435 439.
40. Poppek D., Keck S., Ermak G., Jung T., Stolzing A., Ullrich O., Davies K. J. Grune T. (2006) Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem. J. 400, 511 520.
41. Rankin C. A., Sun Q. Gamblin T. C. (2005) Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Brain Res. Mol. Brain Res. 138, 84 93.
42. Rapoport M., Dawson H. N., Binder L. I., Vitek M. P. Ferreira A. (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA 99, 6364 6369.
43. Rissman R. A., Poon W. W., Blurton-Jones M., Oddo S., Torp R., Vitek M. P., LaFerla F. M., Rohn T. T. Cotman C. W. (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121 130.
44. Rizzu P., Van Swieten J. C., Joosse M. et al. (1999) High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am. J. Hum. Genet. 64, 414 421.
45. Roberson E. D., Scearce-Levie K., Palop J. J., Yan F., Cheng I. H., Wu T., Gerstein H., Yu G. Q. Mucke L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750 754.
46. Santacruz K., Lewis J., Spires T. et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476 481.
47. Schneider A., Biernat J., von Bergen M., Mandelkow E. Mandelkow E. M. (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549 3558.
48. Schneider A., Araujo G. W., Trajkovic K., Herrmann M. M., Merkler D., Mandelkow E. M., Weissert R. Simons M. (2004) Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J. Biol. Chem. 279, 55833 55839.
49. Spittaels K., Van den Haute C., Van Dorpe J. et al. (2000) Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275, 41340 41349.
50. Stamer K., Vogel R., Thies E., Mandelkow E. Mandelkow E. M. (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051 1063.
51. Tanzi R. E. Bertram L. (2001) New frontiers in Alzheimer's disease genetics. Neuron 32, 181 184.
52. Wille H., Drewes G., Biernat J., Mandelkow E. M. Mandelkow E. (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J. Cell Biol. 118, 573 584.
53. Wischik C. M., Harrington C. R., Mukaetova-Ladinska E. B., Novak M., Edwards P. C. McArthur F. K. (1992) Molecular characterization and measurement of Alzheimer's disease pathology: implications for genetic and environmental aetiology. Ciba Found. Symp. 169, 268 293 discussion 293 302.